Advertising
Showing 1 to 15 of 35 entries

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Nov 26/20, Up 32.3%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with BIIB has triggered its stop at $320. We recommend covering the position at this time. We will look for another entry point when value is justified again.
biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Nov 26/20, Up 43%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with BIIB is progressing well. We now recommend trailing up the stop (from $305) to $320. If triggered this would all but guarantee a investment return over 29%, when including the previous recommendation to cover half.
biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK

(A Top Pick Nov 26/20, Up 26.1%)Stochchase Research Editor: Michael O'Reilly Our PAST TOP PICK with CIEN has gapped up through the $305 target. To be disciplined, we recommend trailing up the stop (from $180) to $305. If triggered, this would all but guarantee a minimum investment return over 26%.

biotechnology / pharmaceutical
DON'T BUY
Very high risk, very high reward. Seeing competition on its core drugs. Its Alzheimer's drug didn't get a great reception. Somewhere around June 7 the regulator will rule on this drug. Could be impacted 30% up or 50% down. Not for him.
biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
TOP PICK

Stockchase Research Editor: Michael O'Reilly BIIB has been on a roller-coaster. When the FDA announced a priority review of a new Alzheimer's drug, it stock soared to $360. When the review failed to approve the drug in the first go-round, the stock plunged to under $250 -- so it goes with drug manufacturers. Its MS drugs continue to do well and it is working on treatments for Parkinson's disease as well. Trading at 8x earnings, it is cheap compared to peers at 30x. We would buy this with a $180 stop-loss looking to achieve $305 -- 26% upside. Yield 0%. (Analysts’ price target is $305.90)

biotechnology / pharmaceutical
BUY
The FDA found Biogen's Alzheimer's drug effective and exploded 44% today amid the post-election rally. Overall, healthcare stocks have more room to run. You need to own some healthcare in a portfolio.
biotechnology / pharmaceutical
DON'T BUY

https://www.pmlive.com/pharma_news/fda_sets_november_date_for_expert_panel_review_of_biogens_aducanumab_1351831 Until February 2020, Biogen's FDA results of an Alzheimer drug was the healthcare event of the year (then Covid hit). Novartis and other players are starting to compete here, though. He owned Biogen some years ago. He was on a panel which was split over whether Biogen would get FDA approval on Nov. 6. Regardless, this is a high-risk play; this could pop 35-50% up or down. The risk/return is too much for him. The drug has a checkered past and so far there is no effective Alzheimer's drug, but if it works it will be huge for the company and society.

biotechnology / pharmaceutical
BUY on WEAKNESS
He bought it two months ago. They have a diabetes drug candidate, the only company.. They have a history of above-average returns, which ticks that box. Buy at $250-270 If the drug is approved, he predicts the stock to hit $350-400.
biotechnology / pharmaceutical
DON'T BUY
The sector has done poorly, and the summer is seasonality. A lot of this has to do with the US election campaign with candidates offering cheap/free healthcare. BIIB fell below support at $250. He is avoiding the entire space.
biotechnology / pharmaceutical
SELL
He doesn't like their chart. Sell if it closes below $220. Institutions are selling it, and it's selling on weak volume. Had a big breakdown in latter 2018. Look elsewhere.
biotechnology / pharmaceutical
COMMENT
Demonstrates how binary risk can happen in individual securities. Big driver recently has been failure in an Alzheimer's study. Had to shut the study down, which caught the market by surprise. Likes it, though risk in this stock is high, with a relatively high rate of return. For all large cap biotech, make sure you have at least a couple of positions.
biotechnology / pharmaceutical
DON'T BUY
Indicators are quite oversold. Lots of action around $219 from 2013. He very rarely plays individual biotech names for this very reason. It's high beta, so it's more volatile than the market. He prefers to buy the biotech ETF. If it breaks $198, it will probably go to $150.
biotechnology / pharmaceutical
TOP PICK

A large bio-pharma. They enjoyed a recent jump in the stock price had to do with seeing promising results from a phase 2 trial drug treating Alzheimer's. If this drug ultimately passes, it would be an multi-billion-dollar opportunity. Free cash flow is a high 7%. They'll likely make an acqusition with all this cash to deepend their portfolio. (Analysts' price target: $365.00)

biotechnology / pharmaceutical
DON'T BUY

He Prefers VRTX-Q. You need to invest in the most innovative companies in this sector.

biotechnology / pharmaceutical
PAST TOP PICK

A situation where the market is nervous, the stock slips, which then creates opportunity. Investors won't pay these kinds of multiples out of uncertainty. Biogen is focussed on developing solutions for MS; their Alzheimer's drug is in phase 3 testing, which he personally hopes works. Be patient. BIIB will bounce around with failed drug tests, but this company will yield winning drugs.

biotechnology / pharmaceutical
Showing 1 to 15 of 35 entries

Biogen IDEC Inc.(BIIB-Q) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 5

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 7

Stockchase rating for Biogen IDEC Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Biogen IDEC Inc.(BIIB-Q) Frequently Asked Questions

What is Biogen IDEC Inc. stock symbol?

Biogen IDEC Inc. is a American stock, trading under the symbol BIIB-Q on the NASDAQ (BIIB). It is usually referred to as NASDAQ:BIIB or BIIB-Q

Is Biogen IDEC Inc. a buy or a sell?

In the last year, 7 stock analysts published opinions about BIIB-Q. 5 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Biogen IDEC Inc..

Is Biogen IDEC Inc. a good investment or a top pick?

Biogen IDEC Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Biogen IDEC Inc..

Why is Biogen IDEC Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Biogen IDEC Inc. worth watching?

7 stock analysts on Stockchase covered Biogen IDEC Inc. In the last year. It is a trending stock that is worth watching.

What is Biogen IDEC Inc. stock price?

On 2021-10-20, Biogen IDEC Inc. (BIIB-Q) stock closed at a price of $266.57.